Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Gastroesophageal reflux disease (GERD) - symptomatic relief and healing of erosive esophagitis.
* H. pylori eradication (in combination with antibiotics).
* Zollinger-Ellison syndrome and other pathological hypersecretory conditions.
* Prevention of NSAID-induced gastric ulcers.
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or intravenously once daily. For healing, may be continued for up to 8 weeks. For long-term maintenance, doses of 20-40 mg once daily may be used.
* **H. pylori Eradication:** 40 mg orally twice daily in combination with antibiotics for 7-14 days.
* **Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome):** Starting dose is typically 40 mg orally or intravenously twice daily. Doses may be adjusted based on gastric acid output. Doses up to 240 mg intravenously daily have been used.
* **NSAID-Induced Ulcer Prevention:** 20 mg orally once daily.
## Pediatric Dosing
* **GERD/Erosive Esophagitis:**
* **12 years and older:** 40 mg orally once daily. Dosing duration up to 8 weeks.
* **5 to less than 12 years:** 20 mg orally once daily. Dosing duration up to 8 weeks.
* **Less than 5 years:** Efficacy and safety not established for oral formulations in this age group. IV formulation data is limited. Consult specialized pediatric resources.
## Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 20 mg once daily for oral or IV administration.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
* Common: Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
* Serious:
* **Long-term use:** Increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), vitamin B12 deficiency, hypomagnesemia.
* Acute interstitial nephritis.
* Rebound acid hypersecretion upon discontinuation.
* Fundic gland polyps.
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Ketoconazole, itraconazole, iron salts, ampicillin esters, mycophenolate mofetil. Pantoprazole can decrease absorption.
* **Methotrexate:** PPIs may increase methotrexate levels.
* **CYP2C19 substrates:** Pantoprazole can inhibit CYP2C19, potentially affecting metabolism of drugs like clopidogrel (though clinical significance is debated and often not considered clinically significant for clopidogrel).
* **St. John's Wort:** May decrease pantoprazole levels.
## Monitoring
* Electrolytes (magnesium, calcium, potassium) with long-term therapy.
* Bone mineral density with prolonged treatment.
* Symptoms of GI infection (e.g., *C. difficile*).
* For hypersecretory conditions, monitor gastric acid output.
## Clinical Pearls
* Administer 30-60 minutes before a meal for optimal efficacy.
* Delayed-release tablets should be swallowed whole and not chewed or crushed.
* IV formulation should be reconstituted and diluted per manufacturer's instructions.
* Discontinuation should ideally be tapered to avoid rebound acid hypersecretion.
***
*This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for complete details and to ensure patient safety. Dosing may vary based on individual patient factors and local protocols.*
